Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Shareholder Meeting (November 2018)
11 slides from Pyc Therapeutics's shareholder meeting presentation, Nov 16, 2018
Slide 1: Phylogica AGM Presentation November 2018
For personal use only Phylogica AGM Presentation November 2018 1
Slide 2: We are solving one of the most important challenges in pharmacology
We are solving one of the most important challenges in pharmacology For personal use only Delivering large molecules inside cells to reach ‘undruggable’ …Where success is commensurately targets is one of the biggest rewarded (even in early-stage challenges in modern drug companies) development… Pre-
Slide 3: Cell Penetrating Peptides (CPPs) sit on the cusp of clinical validation
Cell Penetrating Peptides (CPPs) sit on the cusp of clinical validation For personal use only Sarepta have taken promising pre- clinical results driven by Cell …Into the clinic Penetrating Peptides (CPPs)… i) CPP-PMO (PPMO) is now in Phase 1 trials ii) multiple follow on CPP-PMO programs are schedul
Slide 4: Phylogica has a major competitive advantage in CPPs
Phylogica has a major competitive advantage in CPPs For personal use only We have the richest and most …And we are translating this structurally diverse source library for advantage from the libraries into Cell Penetrating Peptides (CPPs)… our ‘platform’ Comparison of efficiency of Phylogica’s CPPs
Slide 5: We have a clear path to translate our differentiation into 'a molecule'
We have a clear path to translate our differentiation into ‘a molecule’ For personal use only 2019 2020 Development Pre-clinical IND-enabling Clinical stage Milestone Interim Definitive IND-submission in vivo (therapeutic) read-outs in vivo read- out Cargo Reporter Therapeutic Therapeutic Therapeuti
Slide 6: We will soon realise a major milestone in validating our platform
We will soon realise a major milestone in validating our platform For personal use only 2018 2019 Maturity of data: Proof of Concept in vivo Therapeutic in vivo BD discussions: Risk-driven ‘small’ deals Value-driven ‘market based’ deals Driver of company Lead asset Platform valuation: Therapeutic in
Slide 7: We will achieve this objective with an Anti-Sense Oligonucleotide (ASO) cargo
We will achieve this objective with an Anti-Sense Oligonucleotide (ASO) cargo For personal use only ASOs have weak intrinsic cell ASOs are an emerging class of penetrating properties therapeutics “The great thing about this PMO “Oligonucleotide therapeutics have the technology is that it's precise a
Slide 8: In 2019 we will…
In 2019 we will… For personal use only 1) Deliver the data that matters - therapeutic in vivo validation 2) Use the richness of our data (number and quality of CPPs) to: - tailor CPPs to our cargo and target of interest; and - refresh our Intellectual Property estate with a broad ‘rule based’ claim
Slide 9: Phylogica's value proposition
Phylogica’s value proposition For personal use only 1) A ‘best in class’ Cell Penetrating Peptide (CPP) platform 2) That is highly scalable 3) At a time when CPPs are reaching the ‘tipping point’ of clinical validation 4) With major technical milestones within reach (therapeutic in vivo read-outs) 5
Slide 10: Thank you
For personal use only Thank you For more information contact Dr. Rohan Hockings rohanhockings@phylogica.com 10
Slide 11: Disclaimer
Disclaimer For personal use only The purpose of the presentation is to provide an update on the business of Phylogica Limited (ASX:PYC) [‘Phylogica’]. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Acc